Real-Time Process Analytical Technology (PAT) for Continuous Production Monitoring
Advanced bioanalytics, as part of modern process analytical technology systems, play a pivotal role in the success of biomanufacturing by providing crucial insights into process development and ensuring stringent quality control. In biopharmaceutical production, these tools enable real-time bioprocess monitoring of variables like cell culture conditions, protein expression, and purification processes, ensuring both efficiency and product consistency.
Most PAT tools, however, were built to monitor the bioreactor, not the cell. Sensors for pH, dissolved oxygen, and metabolite concentration tell you about the environment cells are growing in, but say very little about the health, viability, or phenotype of the cell population itself, which is the actual product in cell and gene therapy manufacturing. That gap is where cellular PAT comes in: applying the same real-time, in-process philosophy of PAT directly to single-cell-level Critical Quality Attributes (CQAs), not just bulk media chemistry.
The precision afforded by advanced bioanalytics not only enhances the efficiency of biomanufacturing processes but also ensures the consistency and quality of the final product. From accelerating process development to guaranteeing adherence to regulatory standards, these tools are indispensable in the pursuit of robust and reliable biomanufacturing practices, ultimately contributing to the production of safe and effective biotherapeutics.
The Challenge
Current analytical challenges for biomanufacturing include the characterization of complex processes and products, including viruses and mammalian cells. In contrast to small molecules, which can be characterized using well-defined techniques, these advanced therapies often require time-consuming and resource-intensive analysis. Traditional PAT tools rely on bulk physical and chemical measurements, leaving a critical blind spot: they cannot resolve individual cell‑level Critical Process Parameters (CPPs) in real time. As a result, they miss the biochemical shifts, viability changes, and morphological responses that signal when cells are drifting from optimal performance. Without this cellular resolution, teams are forced to make high‑stakes decisions using lagging, population‑averaged indicators — increasing variability, risk, and the likelihood of costly downstream failures. Another hurdle is integrating real-time, high-throughput analytics into biomanufacturing workflows, necessitating innovative solutions to ensure efficient and reliable monitoring of critical parameters.
Our Solution
LumaCyte’s Radiance® transforms single‑cell biochemical and biophysical data into immediate, actionable manufacturing intelligence — enabling rapid in‑run decisions, adaptive process adjustments, and stronger, regulator‑ready documentation. By resolving how individual cells respond to their environment, Radiance® gives teams the real‑time insight needed to maintain control, protect yield, and demonstrate deep process understanding.
Manufacturing teams use this data to:
- Adjust process conditions in time to save a batch, correcting early cellular declines before they cascade into yield or quality failures
- Trigger adaptive manufacturing steps based on emerging biochemical changes observed at the single‑cell level
- Optimize feeding, aeration, or agitation before productivity drops, guided by real‑time cellular behavior
- Confirm culture stability without waiting for downstream assays, supporting continuous monitoring expectations
- Reduce reliance on post‑production analytics that delay decisions and complicate late‑stage corrective actions
Because Radiance® delivers precise cellular response metrics in minutes, teams can respond immediately — tightening process control, preventing yield loss, and generating robust data packages that strengthen regulatory interactions and demonstrate proactive, science‑based quality control strategies and manufacturing oversight.
Cellular-Level Critical Quality Attributes, In Real Time
Radiance® resolves CQAs, viability, size, and morphology, at the single-cell level as the process runs, closing the blind spot left by bulk PAT sensors that can only characterize the surrounding media.
Accelerated Time to Result
The platform enables real-time cellular data for rapid process optimization, reducing the time to result and allowing for adjustments during the run rather than after it, when the batch can no longer be corrected.
Regulatory-Aligned Quality Control
Radiance® generates robust cell‑level CQA and CPP data in minutes, providing the high‑resolution, real‑time evidence that FDA’s PAT and Quality by Design (QbD) frameworks expect. This level of cellular insight strengthens documentation, supports real‑time release testing (RTRT), and demonstrates deep process understanding — helping teams justify decisions, respond to regulators with confidence, and streamline the path toward continuous bioprocessing.
Cellular PAT Across the Bioprocess Lifecycle
LumaCyte’s Laser Force Cytology™ and Radiance® instrument deliver real-time, label-free single-cell analysis at every stage of biomanufacturing, so process teams get high-quality cellular PAT data no matter where in the workflow they need it.
Across the lifecycle, Radiance® provides consistent, high‑resolution cellular PAT data that strengthens regulatory workflows, streamlines comparability assessments, and de‑risks and accelerates technical transfer across sites and users. By delivering the same cell‑level CQAs and CPPs at every stage and scale, teams gain a unified data foundation that supports confident process changes, smoother regulatory interactions, and reliable performance across sites and partners.
Why Cellular PAT Matters for Biomanufacturing Quality
Cell‑Level Response Metrics, Because They Define Performance
Radiance® quantifies the biochemical and biophysical response of individual cells to the bioreactor environment — the real‑time cellular behavior that determines product quality, stability, and process performance. By resolving these cell‑level response metrics, Radiance® closes the blind spot left by bulk PAT tools and is recognized in ISO 8934‑1, the global standard for cell viability analytical methods. Within this standard, LumaCyte’s optical and fluidic force measurements are highlighted for their ability to generate fit‑for‑purpose viability data that predicts downstream performance — providing a more functional, forward‑looking view of cellular health than traditional membrane‑integrity assays.
Faster Process Development Decisions
Because cellular data is available in minutes instead of days, process and manufacturing teams can rapidly optimize and accelerate scale-up during development rather than waiting on offline assay turnaround. (See Process Optimization & Scale-Up for a deeper look.)
Contamination and Deviation Detection
Radiance® detects contamination at the cellular‑response level days before a bioreactor turns cloudy. By measuring early biochemical and biophysical shifts in individual cells, Radiance® surfaces the first signs of bacterial or fungal intrusion long before turbidity or color change appear. This advance warning allows teams to identify contamination early, terminate compromised runs sooner, and prevent contaminated material from moving upstream or downstream — saving time, protecting equipment and resources, and reducing overall cost and operational disruption.
Improved Product Quality and Yield
Experience a substantial boost in product quality and yield through the real-time analysis of Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) with Radiance®, ensuring consistently superior outcomes.
Detection of Spiked Adventitious Virus in a Live Viral Vaccine Using Laser Force Cytology™
Here, samples were collected from Vero cells growing on microcarriers in a bioreactor. Changes in the optical force index distribution and other LFC™ data demonstrate the capability of Radiance® to differentiate between different viral conditions as a means of rapidly detecting changes in process condition. This same cellular PAT approach also applies to viral vector production monitoring and vaccine potency assays. LFC’s capability to detect viral process changes is now further reinforced by ISO 16921-2, which formally recognizes LumaCyte’s method for viral vector quantification.
Frequently Asked Questions About Cellular PAT for Biomanufacturing
What is Process Analytical Technology (PAT) in biomanufacturing?
Process Analytical Technology (PAT) is an FDA-endorsed framework for designing, analyzing, and controlling manufacturing through timely measurement of Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs). In biomanufacturing, PAT is traditionally applied to bulk process variables such as pH, dissolved oxygen, and metabolite levels.
What is cellular PAT, and how is it different from traditional PAT tools?Section
Cellular PAT extends the PAT framework to the individual cell level. Instead of only measuring the media a cell population is growing in, cellular PAT instruments like Radiance® quantify cell-level CQAs, enabling biochemical and biophysical cellular response metrics in real time and without the need for labels or fluorescents, giving visibility into the product itself rather than only its surrounding environment. Cellular PATs deliver a more comprehensive and robust quality control strategy with a newer industry term of PACT being adopted, which adds “control” to the PAT acronym.
Can PAT tools measure cell-level Critical Quality Attributes (CQAs)?
Most conventional PAT sensors cannot. They are designed to monitor bulk physical and chemical conditions. LumaCyte’s Radiance®, built on Laser Force Cytology™, is designed specifically to resolve single-cell CQAs in minutes, addressing a measurement gap left by bulk-only PAT instrumentation.
How does Radiance® support real-time release testing (RTRT)?
Radiance® supports RTRT by delivering continuous, in‑process cellular data that proves CQAs are controlled as the batch runs — not after it ends. Instead of relying on slow offline assays, Radiance® provides real‑time cell‑level CQA data and cellular response metrics that show the culture is stable and on‑spec throughout the run. This evidence aligns with FDA PAT and QbD expectations and enables RTRT strategies built on real‑time process understanding rather than end‑of‑batch testing.
Does LumaCyte's cellular PAT approach align with FDA guidance and Quality by Design (QbD)?
Yes. Radiance®’s cellular PAT approach aligns with FDA PAT and QbD guidance by generating real‑time, in‑process data that demonstrates control of CQAs as the batch runs — building quality into the process rather than testing for it afterward. This continuous cell‑level characterization also supports FDA CMC and potency expectations, which increasingly call for comprehensive in‑process monitoring and matrix assay strategies to establish functional, mechanism‑linked measures of product quality. Radiance® biochemical and biophysical response metrics provide the kind of multi‑attribute, real‑time evidence regulators look for when assessing process understanding, potency justification, and the robustness of a control strategy.
Has LumaCyte's cellular PAT technology been incorporated into any ISO standards?
Yes, in 2026 LumaCyte’s Laser Force Cytology™ methods were published in two global ISO standards: ISO 8934-1 for cell viability analytical methods, and ISO 16921-2 for viral vector quantification. Together, these standards reflect growing international recognition for advanced analytics and the value of label-free, single-cell measurement as an approach for improved biomanufacturing quality control strategies. Read more on how ISO 16921-2 applies to viral vector measurement, or why cell vitality matters in living therapies.
Cellular Early Warning, Because Drift Starts at the Cell Level
Bulk PAT sensors can signal that something has shifted. Radiance® shows when cells themselves begin trending out of specification — revealing early biochemical and biophysical responses that emerge long before pH, DO, or turbidity move. Because cells sense environmental drift first, Radiance® provides the real‑time insight needed to understand cellular response behavior, identify early process deviations, and unlock adaptive manufacturing strategies grounded in cell‑level data.
If your team is evaluating PAT approaches for cell therapy, gene therapy, or viral vector production, our scientists can walk you through real single‑cell response data from processes similar to yours so you can see how early cellular trends reveal stability, drift, and emerging variability in real time.
